Quick Facts

• Dogs: Addresses and prevents acute vomiting, and prevents vomiting due to motion sickness. Also prevents emesis related to chemotherapy.
• Cats: Used to address vomiting and reduce nausea. May also be utilized to prevent emesis.

---

Therapeutic Use and Benefits

Cerenia (maropitant citrate) is indicated for addressing and preventing episodes of vomiting in companion animals. In dogs, the authorized uses include the treatment and prevention of acute vomiting. It is also approved for the prevention of vomiting specifically caused by certain agents, such as chemotherapeutic drugs, and for preventing vomiting due to motion sickness.

For felines, the injection formulation is approved for the treatment of vomiting. The medication may also be utilized to help prevent vomiting and reduce symptoms of nausea in cats. The benefits of therapeutic use include the control of emesis, which may mitigate associated complications such as dehydration and electrolyte imbalance. Furthermore, controlling perioperative vomiting in dogs has been shown to support improved recovery after general anesthesia.

Regulatory References

1. EMA therapeutic overview

Official Eligibility and Population Restrictions

Cerenia's eligibility profile is strictly defined by regulatory standards concerning the animal’s age and physiological status. The profile is structured around established safety criteria, defining who may use the drug, who is restricted to conditional use, and for whom the safety profile is not established.

Age-Based Eligibility: Use is established for different age groups based on the indication:

• Dogs (Acute Vomiting): Approved for dogs 8 weeks of age and older.
• Dogs (Motion Sickness): Approved for dogs 16 weeks of age and older (4 months).
• Cats (Injectable): Approved for cats 16 weeks of age and older.

Conditional Use and Non-Established Safety: The medicine's safe use has not been evaluated in several critical populations, restricting its use:

• Use Not Established: Safe use has not been evaluated in animals used for breeding, or in pregnant or lactating dogs and cats (bitches or queens).
• Conditional Caution: Caution is advised for patients with hepatic (liver) dysfunction and animals with a predisposition for cardiac diseases.
• Acute Restrictions: Safety has not been evaluated in animals with suspected Gastrointestinal Obstruction or those that have ingested toxins.

Interactions with other medicines and products

The official regulatory profile for maropitant citrate focuses on pharmacokinetic constraints and a formal prohibition based on its pharmacological properties.

Interaction Classifications

The drug is subject to both a formal contraindication and cautions regarding co-administration with specific medicine classes.

Classification	Interacting Category	Official Regulatory Constraint
Contraindication	Calcium-channel antagonists	Concomitant use is prohibited due to the affinity of maropitant to Ca-channels.
Caution	Inhibitors of CYP3A and CYP2D15	Caution is required, as this may increase maropitant plasma concentration by inhibiting its metabolism.
Caution	Highly protein-bound medicines	May lead to competitive plasma protein binding, potentially altering free concentrations of either drug.

---

Official Interaction Statements

Maropitant citrate is metabolized primarily by the Cytochrome P450 enzymes CYP3A and CYP2D15. Regulatory documents advise caution when co-administering with medicines known to inhibit these enzymes, which may result in altered systemic exposure. Furthermore, due to its high plasma protein binding (greater than 99%), maropitant may compete with other highly bound medicines, including NSAIDs and certain cardiac medications. The official profile also includes a population-specific constraint, noting that caution is warranted in patients with hepatic dysfunction because the liver is the main site of drug clearance.

Final Common Pathway Inhibition

This mechanism centers on the drug's function as a highly specific antagonist for the Neurokinin-1 ( NK1) receptor . By competitively binding to this receptor, the drug prevents the essential neuropeptide, Substance P, from carrying out its signaling role. Blocking this molecular step disables the final signal required to initiate the expulsion reflex, resulting in a direct physiological suppression of the central command center's activity.

---

Dual Central and Peripheral Action

The drug's mechanism involves dual pathway control, influencing the reflex at both the periphery and the center. The drug blocks NK1 receptors centrally within the brain's vomiting center and the chemoreceptor trigger zone ( CRTZ), while also blocking peripheral NK1 receptors located in the gastrointestinal tract. This simultaneous inhibition of both visceral signals and central commands contributes to the dampening of the entire network required to trigger the reflex, leading to a broad physiological suppression of the response network.

How Cerenia is Used: Administration Guidelines

Maropitant citrate (Cerenia) is administered once daily and is used according to specific, dose-dependent, and age-restricted regimens.

Administration Routes and Dosage

Cerenia is used via three routes, with corresponding minimum daily doses:

Indication / Context	Formulation and Route	Minimum Dose	Age Constraint (Minimum)
Acute Vomiting (Treatment/Prevention)	Oral Tablets	2 mg/kg	2 months and older (Dogs)
Acute Vomiting (Treatment/Prevention)	Injectable Solution (SC/IV)	1 mg/kg	2 months and older (Dogs); 4 months and older (Cats)
Motion Sickness (Prevention)	Oral Tablets	8 mg/kg	4 months and older (Dogs)

For actively vomiting dogs, treatment should be initiated with the injectable solution (1 mg/kg) to ensure the full initial dose is administered. Oral tablets (2 mg/kg) may be used for subsequent daily doses.

---

Timing and Duration of Use

• Acute Vomiting: Oral tablets for dogs 7 months and older may be dosed once daily until resolution. For dogs 2-7 months of age, and all injectable use (Dogs/Cats), treatment is limited to up to 5 consecutive days.
• Motion Sickness: The oral dose (8 mg/kg) is limited to up to 2 consecutive days. The tablet should be administered at least one to two hours prior to the journey.
• Chemotherapy: For prevention of emesis, the injectable solution (1 mg/kg) should be administered 45 to 60 minutes prior to the chemotherapeutic agent.

---

Administration Requirements

• Tablets: For motion sickness, the tablets should be given with a small amount of food or snack but should not be wrapped in food as this may delay dissolution and onset of effect. A full meal should be avoided prior to travel.
• Injections: Intravenous (IV) administration of the 1 mg/kg solution should be given slowly over 1-2 minutes. Using a refrigerated injectable product may reduce the pain response associated with the subcutaneous (SC) injection.

The case should be re-evaluated if vomiting persists despite adherence to the use instructions.

Research Evidence / Overview of Studies for Cerenia

Evidence for Use in Treating Acute Vomiting

Research for Maropitant Citrate includes short-term, randomized controlled trials (RCTs) and clinical field studies that research explored the medicine's role in conditions associated with acute or disruptive episodes of vomiting in the populations studied. These studies were applied in research contexts involving fluctuating or unstable symptoms and measured outcomes related to physical discomfort by monitoring the frequency of vomiting events. The populations was evaluated in dogs (from 2 months old) and cats (from 4 months old) with acute emesis resulting from various medical conditions.

In these trials, the findings describe patterns observed in the studies related to the cessation of vomiting compared to control groups. These studies report how symptoms evolved in the observed populations during the short-term treatment period. Research describes patterns related to measured changes in the frequency of emesis, contributing to the broader body of research.

---

Evidence for Prevention of Specific Types of Vomiting

Controlled trials specifically designed to assess the medicine’s role in research exploring short-term symptom changes related to vomiting triggered by known events have been conducted. One area was studied for its role related to vomiting associated with highly emetogenic chemotherapeutic agents. Separate randomized controlled trials research examined the medicine’s use for monitoring vomiting due to motion sickness. These trials was evaluated in dogs susceptible to travel-related vomiting, with the research describing patterns observed in the studies related to the measured incidence of motion-induced emesis.

---

What the Research Record Indicates as Uncertain

The overall evidence base, while relying on several randomized controlled trials, still contains areas of uncertainty. Evidence quality varies across studies, particularly regarding comparative studies against all alternative treatments. Comparative evidence is lacking in some areas. Long-term effects are not fully established in the publicly available regulatory research summaries, and further research continues to explore the persistence and durability of observed patterns. The research provides context but not individual predictions, meaning the evidence highlights what is known — and what is still uncertain.

Common questions about Cerenia (FAQ)

Q: How quickly does Cerenia usually start to work after being administered?

Official product information, based on clinical studies, describes anti-emetic efficacy starting at approximately one hour after the medicine is administered orally. The highest concentration of the active ingredient in the bloodstream is typically reached around 1.7 to 1.9 hours after dosing.

Q: How long does the anti-nausea effect of Cerenia typically last?

Regulatory documents indicate that the effect of a single dose is approximately 24 hours when used for the treatment or prevention of acute vomiting. For the prevention of motion sickness, the anti-emetic effect persists for at least 12 hours.

Q: Does Cerenia have any anti-inflammatory properties according to research?

The medicine's official and approved uses are restricted to the treatment and prevention of nausea and vomiting. Its mechanism of action involves blocking Substance P at the NK1 receptor, a step critical to the central vomiting reflex. Its approved indications are restricted to the management of nausea and vomiting.

Q: Do the side effects of Cerenia usually stop once the medication is stopped?

Official information generally describes the medicine as short-acting. Most typical effects of the drug are expected to diminish within 24 hours of the last dose. Severe adverse events, such as a rare allergic reaction, are generally expected to resolve after the medicine is discontinued.

Q: Does Cerenia interact with any common antifungal medications?

Official documents state that caution is warranted when the medicine is co-administered with drugs that inhibit Cytochrome P450 (CYP) enzymes in the liver, as this can increase the concentration of Cerenia in the bloodstream. Certain antifungal agents, such as ketoconazole or itraconazole, are known to inhibit these enzymes.

Q: Can Cerenia affect the absorption of other medications given at the same time?

The active ingredient in Cerenia is highly bound to plasma proteins in the blood. Official information indicates this may lead to competition with other highly protein-bound medicines, potentially altering the free concentration of either drug in the bloodstream.

Q: Has Cerenia been studied for use in reducing perioperative nausea and vomiting?

Regulatory research summaries include data on the medicine's use to prevent vomiting induced by certain highly emetogenic (vomiting-causing) agents. This research encompasses preventing vomiting induced by agents like opioids, which are sometimes used in protocols around surgery.

Q: Can Cerenia still be effective if the full 24-hour period has not passed since the last dose?

The prescribed dosing interval is once daily, with an effect lasting approximately 24 hours. Because the drug is known to accumulate in the body after repeated administration, the concentration in the bloodstream may be higher than with a single dose.

Q: What is the proper way to handle Cerenia tablets to avoid personal exposure?

Established safety precautions include using caution when administering the product, particularly for individuals with known sensitivity to the active ingredient. Washing hands after use is an established precaution. In the event of accidental ingestion or contact with the eyes or skin, seeking immediate medical attention is the protocol.

Q: Is Cerenia used to manage pain in addition to its anti-vomiting properties?

The official and approved use of the medicine is restricted solely to the management of nausea and vomiting. While the drug blocks Substance P, a chemical messenger implicated in pain, this action is not an approved indication for the medicine.

How to Store and Dispose of Cerenia (Maropitant Citrate)

The storage and disposal of Cerenia must strictly follow official regulatory guidelines to maintain stability and ensure safety. All forms of the medication must be kept out of the sight and reach of children.

---

Storage Requirements

Formulation	Required Storage Condition	Post-Opening Stability	Restriction
Oral Tablets	Controlled room temperature (20 C to 25 C)	Unused half-tablet: 2 days in blister	Store in original packaging
Injectable Solution	Controlled room temperature (20 C to 25 C)	Refrigerate (2 C to 8 C); use within 90 days	Do not freeze

---

Disposal

Unused or expired Cerenia, including waste materials, must be disposed of according to local requirements. Medicines must not be discarded via wastewater or standard household waste.